Table 1.
Baseline characteristics of the 432 pregnant women who participated in the PACOME trial
| Category | Subcategory | N (%) or mean (SD)* |
|---|---|---|
|
Sociodemographic characteristics |
|
|
| Health centre |
CNHU |
136 (31.5) |
| |
HIA |
76 (17.6) |
| |
CLP |
29 (6.7) |
| |
HZ de Suru Léré |
146 (33.8) |
| |
HOMEL |
45 (10.4) |
| Age (years) (N = 431) |
|
29.2 (4.7) |
| Education |
None or unknown |
117 (27.1) |
| |
Primary |
153 (35.3) |
| |
Secondary |
128 (29.8) |
| |
University |
34 (7.8) |
| Marital status |
Single |
25 (5.8) |
| |
Married (monogam) |
272 (63.0) |
| |
Married (polygam) |
131 (30.2) |
| |
Other or unknown |
4 (1.0) |
|
General and obstetric characteristics |
|
|
| Obesity (BMI ≥30 kg/m2) (N = 427) |
|
52 (12.2) |
| Sickle cell trait (N = 267) |
Homozygote (SS) |
16 (6.0) |
| |
Heterozygote (AS) |
26 (9.7) |
| Primigravid |
|
50 (11.6) |
| Number of live born |
|
1.7 (1.5) |
| Gestational age at inclusion (weeks) |
|
21.7 (3.8) |
| Symptomatic malaria in early pregnancy before inclusion (N = 424) |
|
45 (10.6) |
|
HIV–related characteristics |
|
|
| Time since HIV diagnosis (months)* |
|
15 (1–42)* |
| WHO staging |
1 |
303 (70.1) |
| |
2 |
62 (14.4) |
| |
3 |
65 (15.1) |
| |
4 |
2 (0.5) |
| CD4 cell count (/mm3)* |
|
342 (230–491)* |
| Undetectable viral load (N = 257) |
|
82 (31.9) |
| Cotrimoxazole started before the ongoing pregnancy (N = 430) |
|
204 (47.4) |
| Antiretroviral therapy started before inclusion (N = 429) | 222 (51.8%) |
*Values presented are median and interquartile range.
CNHU, Centre National Hospitalier Universitaire Hubert Koutoukou Maga; HIA, Hôpital d’Instruction des Armées de Cotonou; HOMEL, Hôpital Mère Enfant de la Lagune; CLP, Clinique Louis Pasteur; HZ, Hôpital de Zone.